eligibility_summary
Eligibility: Received tisagenlecleucel in commercial or OOS use and provided informed consent. ALL: ages 0–17 (pediatric) or 18–25 (adults) with relapsed/refractory B‑cell ALL who received infusion. DLBCL/FL: age ≥18 with relapsed/refractory diffuse large B‑cell lymphoma who received infusion. Exclusions: no consent, tisagenlecleucel given within an interventional clinical trial.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Tisagenlecleucel (Kymriah), an autologous, genetically modified CAR‑T cell therapy. Patient T cells are lentivirally transduced to express an anti‑CD19 chimeric antigen receptor with 4‑1BB costimulatory and CD3ζ signaling domains. Mechanism: Upon binding CD19 on B cells, CAR‑T cells activate via CD3ζ/4‑1BB, proliferate, secrete cytokines, and kill targets through perforin/granzyme-mediated cytotoxicity, eliminating CD19+ malignant B cells. Targets: CD19-expressing B lymphocytes in B‑ALL, DLBCL, and FL, key pathways include CAR-triggered T‑cell activation (NFAT/NF‑κB/AP‑1), 4‑1BB costimulation, and effector cytotoxic programs. Study: non-interventional Brazilian registry evaluating real-world effectiveness and safety up to 15 years across ALL, DLBCL, and FL cohorts.